Cited by 222Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychoanalysis and Psychopathology Research

The DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.

Pharmacological Treatment of Obsessive-Compulsive Disorder

Open access

Pittenger, Christopher, Bloch, Michael H.·2014·Psychiatric Clinics of North America

DOI 10.1016/j.psc.2014.05.006PMC PMC4143776

Open this paper in CoChat — free account

Abstract

Obsessive-compulsive disorder (OCD) affects up to 2.5% of the population of the course of a lifetime and produces substantial morbidity. Approximately 70% of patients can experience significant symptomatic relief with appropriate pharmacotherapy. Selective serotonin reuptake inhibitors are the mainstay of pharmacological treatment. These drugs are typically used at higher doses and for longer periods than in depression. Proven second-line treatments include the tricyclic clomipramine and the addition of low-dose neuroleptic medications. OCD refractory to available treatments remains a profound clinical challenge.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.psc.2014.05.006

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders(DSM)
Leong, F. T. L. (2008) · Sage eBooks · doi:10.4135/9781412963978.n182 · Cited by 10,861
Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947
Cognitive-Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents With Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study (POTS) Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.292.16.1969 · Cited by 1,107
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive–compulsive disorder
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Facilitation of Conditioned Fear Extinction by Systemic Administration or Intra-Amygdala Infusions of d-Cycloserine as Assessed with Fear-Potentiated Startle in Rats
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Diagnostic and Statistical Manual of Mental Disorders (DSM)
Cooper, R. (2017) · KNOWLEDGE ORGANIZATION · doi:10.5771/0943-7444-2017-8-668 · Cited by 780
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
Self-citation
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
Self-citation
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406
Efficacy of Fluvoxamine in Obsessive-Compulsive Disorder
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810010038006 · Cited by 391
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Obsessive-Compulsive Disorder
Insel, T. R. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.04390010015002 · Cited by 348
Glutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344
Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)
Soomro, G. M., Altman, D. G., Rajagopal, S., & Oakley Browne, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001765.pub3 · Cited by 342
Untitled work
(1996) · PubMed · Cited by 328
Meta-analysis of the dose-response relationship of SSRI in obsessive–compulsive disorder
Bloch, M. H., McGuire, J., Landeros-Weisenberger, A., Leckman, J. F., & Pittenger, C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.50 · Cited by 317
Self-citation
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314
Self-citation
Obsessive Compulsive Disorder
Hudak, R., & Gannon, J. M. (2022) · Current clinical practice · doi:10.1007/978-3-030-98709-1_5 · Cited by 306
Cognitive Behavior Therapy Augmentation of Pharmacotherapy in Pediatric Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study II (POTS II) Randomized Controlled Trial
Franklin, M. E., Sapyta, J., Freeman, J. B., Khanna, M., Compton, S., Almirall, D., Moore, P., Choate-Summers, M., Garcia, A., Edson, A. L., et al. (2011) · JAMA · doi:10.1001/jama.2011.1344 · Cited by 278
Effectiveness of antidepressants: Meta-analysis of dose-effect relationships in randomised clinical trials
Bollini, P., Pampaliona, S., Tibaldi, G., Kupelnick, B., & Munizza, C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.297 · Cited by 274
Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: A Randomized Clinical Trial
Simpson, H. B., Foa, E. B., Liebowitz, M. R., Huppert, J. D., Cahill, S., Maher, M. J., McLean, C. P., Bender, J., Marcus, S. M., Williams, M. T., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1932 · Cited by 248
Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Inositol treatment of obsessive-compulsive disorder
Fux, M., Levine, J., Aviv, A., & Belmaker, R. H. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.9.1219 · Cited by 209
Multivariate Meta-Analysis of Controlled Drug Studies for Obsessive-Compulsive Disorder
Ackerman, D. L., & Greenland, S. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00012 · Cited by 202
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder
Lafleur, D. L., Pittenger, C., Kelmendi, B., Gardner, T., Wasylink, S., Malison, R. T., Sanacora, G., Krystal, J. H., & Coric, V. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0246-6 · Cited by 200
Self-citation
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177
Self-citation
Glutamate Receptors in Extinction and Extinction-Based Therapies for Psychiatric Illness
Myers, K. M., Carlezon, W. A., & Davis, M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.88 · Cited by 177
Anti-Brain Autoantibodies and Altered Excitatory Neurotransmitters in Obsessive–Compulsive Disorder
Bhattacharyya, S., Khanna, S., Chakrabarty, K., Mahadevan, A., Christopher, R., & Shankar, S. K. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.77 · Cited by 172
Obsessive-Compulsive Disorder
Leonard, H. L., Ale, C. M., Freeman, J. B., Garcia, A. M., & Ng, J. (2005) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.06.002 · Cited by 172
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch, M. H., Wasylink, S., Landeros-Weisenberger, A., Panza, K. E., Billingslea, E., Leckman, J. F., Krystal, J. H., Bhagwagar, Z., Sanacora, G., & Pittenger, C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.028 · Cited by 162
Self-citation
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158
Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study
Ghaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Ashrafi, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.015 · Cited by 152
A Critical Review of Magnetic Resonance Spectroscopy Studies of Obsessive-Compulsive Disorder
Brennan, B. P., Rauch, S. L., Jensen, J. E., & Pope, H. G. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.023 · Cited by 148
A Double-Blind Switch Study of Paroxetine and Venlafaxine in Obsessive-Compulsive Disorder
Denys, D. A. J. P., van Megen, H. J. G. M., van der Wee, N. J. A., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0106 · Cited by 144
N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
Afshar, H., Roohafza, H., Mohammad-Beigi, H., Haghighi, M., Jahangard, L., Shokouh, P., Sadeghi, M., & Hafezian, H. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318272677d · Cited by 136
Double-Blind Treatment With Oral Morphine in Treatment-Resistant Obsessive-Compulsive Disorder
Koran, L. M., Aboujaoude, E. N., Bullock, K. D., Franz, B., Gamel, N. N., & Elliott, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0312 · Cited by 132
Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
Berlin, H. A., Koran, L. M., Jenike, M. A., Shapira, N. A., Chaplin, W. F., Pallanti, S., & Hollander, E. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05266gre · Cited by 129
In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)
Haghighi, M., Jahangard, L., Mohammad-Beigi, H., Bajoghli, H., Hafezian, H., Rahimi, A., Afshar, H., Holsboer‐Trachsler, E., & Brand, S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3067-z · Cited by 113
Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study
Bruno, A., Micò, U., Pandolfo, G., Mallamace, D., Abenavoli, E., Di Nardo, F., D’Arrigo, C., Spina, E., Zoccali, R. A., & Muscatello, M. R. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431751 · Cited by 103
Meta‐analysis of association between obsessive‐compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLC1A1
Stewart, S. E., Mayerfeld, C., Arnold, P. D., Crane, J. R., O'Dushlaine, C., Fagerness, J. A., Yu, D., Scharf, J. M., Chan, E., Kassam, F., et al. (2013) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32137 · Cited by 102
Memantine augmentation for refractory obsessive–compulsive disorder
Pasquini, M., & Biondi, M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.04.013 · Cited by 100
Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder
Dell’Osso, B. M., Nestadt, G., Allen, A., & Hollander, E. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0411 · Cited by 97
Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive–compulsive disorder: a double-blind cross-over study
Fux, M., Benjamin, J., & Belmaker, R. H. (1999) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001546 · Cited by 97
Memantine for Treatment-Resistant OCD
Poyurovsky, M., Weizman, R., Weizman, A., & Koran, L. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2191-a · Cited by 97
Early Onset of Response With Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: A Meta-Analysis
Issari, Y., Jakubovski, E., Bartley, C. A., Pittenger, C., & Bloch, M. H. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09758 · Cited by 92
Self-citation
Differential Efficacy of Memantine for Obsessive-Compulsive Disorder vs. Generalized Anxiety Disorder: An Open-Label Trial
Feusner, J. D., Kerwin, L. E., Saxena, S., & Bystritsky, A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4096 · Cited by 91
Escitalopram prevents relapse of obsessive-compulsive disorder
Fineberg, N. A., Tonnoir, B., Lemming, O. M., & Stein, D. J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.11.005 · Cited by 85
Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder
Pittenger, C., Kelmendi, B., Wasylink, S., Bloch, M. H., & Coric, V. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181727548 · Cited by 83
Self-citation
Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults
Greenberg, W. M., Benedict, M. M., Doerfer, J., Perrin, M., Panek, L., Cleveland, W. L., & Javitt, D. C. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.10.007 · Cited by 80
Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial
Mowla, A., Khajeian, A., Sahraian, A., Chohedri, A., & Kashkoli, F. (2010) · CNS Spectrums · doi:10.1017/s1092852912000065 · Cited by 79
Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder
Koran, L. M., Aboujaoude, E., & Gamel, N. N. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04605 · Cited by 79 · cited 1×
“Both dextroamphetamine and caffeine led to significant improvements in refractory patients over 5 weeks [60].”
Background
A double‐blind, placebo‐controlled pilot study of ondansetron for patients with obsessive‐compulsive disorder
Soltani, F., Sayyah, M., Feizy, F., Malayeri, A., Siahpoosh, A., & Motlagh, I. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1145 · Cited by 78
Naloxone administration in obsessive-compulsive disorder: report of two cases
Insel, T. R., & Pickar, D. (1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.9.1219 · Cited by 76
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
Krystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.002 · Cited by 76
Comparative efficacy of antidepressants in preventing relapse in anxiety disorders — A meta-analysis
Donovan, M. R., Glue, P., Kolluri, S., & Emir, B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.021 · Cited by 76
Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Pallanti, S., Quercioli, L., & Koran, L. M. (2002) · PubMed · Cited by 73
Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder
Brandl, E. J., Tiwari, A. K., Zhou, X., Deluce, J. E., Kennedy, J. L., Müller, D., & Richter, M. A. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.12 · Cited by 71
Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
Szegedi, A., Wetzel, H., Leal, M., Härtter, S., & Hiemke, C. (1996) · PubMed · Cited by 67
Venlafaxine in Treatment-Resistant Obsessive-Compulsive Disorder
Hollander, E., Friedberg, J. P., Wasserman, S., Allen, A., Birnbaum, M., & Koran, L. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0508 · Cited by 66
Ondansetron Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
Pallanti, S., Bernardi, S., Antonini, S., Singh, N., & Hollander, E. (2009) · CNS Drugs · doi:10.2165/11530240-000000000-00000 · Cited by 66
Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder
Askari, N., Moin, M., Sanati, M. H., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Najand, B., Salimi, S., Tabrizi, M. H., Ashrafi, M., et al. (2012) · CNS Drugs · doi:10.2165/11635850-000000000-00000 · Cited by 65
Nutraceuticals in the treatment of Obsessive Compulsive Disorder (OCD): A review of mechanistic and clinical evidence
Camfield, D., Sarris, J. J., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.02.011 · Cited by 62
Citalopram Treatment of Compulsive Shopping
Pallanti, S., Quercioli, L., & Koran, L. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0908 · Cited by 61
Complementary medicine, self-help, and lifestyle interventions for Obsessive Compulsive Disorder (OCD) and the OCD spectrum: A systematic review
Sarris, J., Camfield, D., & Berk, M. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.051 · Cited by 59 · cited 1×
“There has been significant interest in a variety of over-the-counter (OTC) agents for OCD [61, 62].”
Background
Lamotrigine Augmentation of Serotonin Re-Uptake Inhibitors in Obsessive–Compulsive Disorder
Kumar, T. C. R., & Khanna, S. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2000.0751c.x · Cited by 59
Effectiveness of Long-Term Augmentation with Citalopram to Clomipramine in Treatment-Resistant OCD Patients
Marazziti, D., Golia, F., Consoli, G., Presta, S., Pfanner, C., Carlini, M., Mungai, F., & Dell’Osso, M. C. (2008) · CNS Spectrums · doi:10.1017/s1092852900014024 · Cited by 45
Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: Improvement with treatment and worsening following discontinuation
Pallanti, S., Bernardi, S., Antonini, S., Singh, N., & Hollander, E. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.003 · Cited by 42
Sarcosine Therapy for Obsessive Compulsive Disorder
Wu, P.-L., Tang, H., Lane, H., Tsai, C., & Tsai, G. E. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182189878 · Cited by 40
Pharmacogenetics of Obsessive–Compulsive Disorders
Brandl, E. J., Müller, D. J., & Richter, M. A. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.133 · Cited by 40
Obsessive Compulsive Disorder
Soomro, G. M. (2012) · Springer eBooks · doi:10.1007/springerreference_223981 · Cited by 32
Genetics and Personalized Medicine in Antidepressant Treatment
Gvozdic, K., Brandl, E. J., Taylor, D. L., & Müller, D. J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523617 · Cited by 25
Safety of High-Dosage Citalopram
Zivin, K., Pfeiffer, P. N., Bohnert, A. S. B., Ganoczy, D. A., Blow, F. C., Nallamothu, B. K., & Kales, H. C. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13081052 · Cited by 13
Citalopram, escitalopram, and the QT interval.
(2013) · PubMed · Cited by 1
Convergent and divergent validity of the Beck Anxiety Inventory for patients with panic disorder and agoraphobia
de Beurs, E., Wilson, K. A., Chambless, D. L., Goldstein, A. J., & Feske, U. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)6:4

Sorted by citations

Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder
Goodman, W. K., Storch, E. A., & Sheth, S. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111601 · Cited by 281
Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta-analysis
Farhat, L. C., Olfson, E., Nasir, M., Levine, J. L. S., Li, F., Miguel, E. C., & Bloch, M. H. (2020) · Depression and Anxiety · doi:10.1002/da.23028 · Cited by 133
Self-citation
Variability and anatomical specificity of the orbitofrontothalamic fibers of passage in the ventral capsule/ventral striatum (VC/VS): precision care for patient-specific tractography-guided targeting of deep brain stimulation (DBS) in obsessive compulsive disorder (OCD)
Makris, N., Yogesh Rathi, A., Mouradian, P., Bonmassar, G., Papadimitriou, G., Ing, W. I., Yeterian, E. H., Kubicki, M. R., Eskandar, E. N., Wald, L. L., et al. (2015) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9462-9 · Cited by 129
DISSECTING OCD CIRCUITS: FROM ANIMAL MODELS TO TARGETED TREATMENTS: Review: Dissecting OCD Circuits: Animals to Treatments
Ahmari, S. E., & Dougherty, D. D. (2015) · Depression and Anxiety · doi:10.1002/da.22367 · Cited by 128

See all 222

Authors: Pittenger, C., & Bloch, M. H.
Affiliations: Yale University (US)
Corresponding author: Pittenger, Christopher
ORCID: Pittenger, Christopher
Bloch, Michael H.
Venue: Psychiatric Clinics of North America
Publisher: Elsevier BV
Published: 2014-09
Volume: 37
Issue: 3
Pages: 375-391
ISSN: 0193-953X (ISSN-L)
DOI: 10.1016/j.psc.2014.05.006
PMC: PMC4143776
OpenAlex: W1997452831
Cited by: 222
References: 79
Citations by year: 2026: 24 · 2025: 25 · 2024: 31 · 2023: 32 · 2022: 21 · 2021: 16 · 2020: 17 · 2019: 16 · 2018: 8 · 2017: 7 · 2016: 12 · 2015: 10 · 2014: 1
FWCI: 1.52
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Psychiatric Clinics of North America (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR000142)
National Institute of Mental Health (R01MH095790, R34MH083115, K23MH091240, R25MH077823)
National Center for Advancing Translational Sciences
Topics: Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords: obsessive-compulsive disorder, pharmacotherapy, selective serotonin reuptake inhibitors, clomipramine, tricyclic antidepressants, treatment-resistant OCD, second-line therapy
MeSH terms: Combined Modality Therapy, Drug Therapy, Combination, Nonprescription Drugs, Humans, Obsessive-Compulsive Disorder, Psychotherapy, Psychotropic Drugs, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacological Treatment of Obsessive-Compulsive Disorder

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks